{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:19:36Z","timestamp":1782317976257,"version":"3.54.5"},"reference-count":33,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Key R&amp;D Program of Zhejiang","award":["No. 2022C03137"],"award-info":[{"award-number":["No. 2022C03137"]}]},{"name":"Key R&amp;D Program of Zhejiang","award":["No. LGF21H080003"],"award-info":[{"award-number":["No. LGF21H080003"]}]},{"name":"Key R&amp;D Program of Zhejiang","award":["No. 2020-3-011"],"award-info":[{"award-number":["No. 2020-3-011"]}]},{"name":"Public Technology Application Research Program of Zhejiang, China","award":["No. 2022C03137"],"award-info":[{"award-number":["No. 2022C03137"]}]},{"name":"Public Technology Application Research Program of Zhejiang, China","award":["No. LGF21H080003"],"award-info":[{"award-number":["No. LGF21H080003"]}]},{"name":"Public Technology Application Research Program of Zhejiang, China","award":["No. 2020-3-011"],"award-info":[{"award-number":["No. 2020-3-011"]}]},{"name":"Key Project of Jinhua Science and Technology Plan, China","award":["No. 2022C03137"],"award-info":[{"award-number":["No. 2022C03137"]}]},{"name":"Key Project of Jinhua Science and Technology Plan, China","award":["No. LGF21H080003"],"award-info":[{"award-number":["No. LGF21H080003"]}]},{"name":"Key Project of Jinhua Science and Technology Plan, China","award":["No. 2020-3-011"],"award-info":[{"award-number":["No. 2020-3-011"]}]},{"name":"2019\u20132024 Academician Workstation of the Fourth Affiliated Hospital of the Zhejiang University School of Medicine","award":["No. 2022C03137"],"award-info":[{"award-number":["No. 2022C03137"]}]},{"name":"2019\u20132024 Academician Workstation of the Fourth Affiliated Hospital of the Zhejiang University School of Medicine","award":["No. LGF21H080003"],"award-info":[{"award-number":["No. LGF21H080003"]}]},{"name":"2019\u20132024 Academician Workstation of the Fourth Affiliated Hospital of the Zhejiang University School of Medicine","award":["No. 2020-3-011"],"award-info":[{"award-number":["No. 2020-3-011"]}]},{"name":"2019\u20132022 Key Medical Discipline (Haematology) Fund of Jinhua, China","award":["No. 2022C03137"],"award-info":[{"award-number":["No. 2022C03137"]}]},{"name":"2019\u20132022 Key Medical Discipline (Haematology) Fund of Jinhua, China","award":["No. LGF21H080003"],"award-info":[{"award-number":["No. LGF21H080003"]}]},{"name":"2019\u20132022 Key Medical Discipline (Haematology) Fund of Jinhua, China","award":["No. 2020-3-011"],"award-info":[{"award-number":["No. 2020-3-011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>A proportion of patients with somatic variants show resistance or intolerance to TKI therapy, indicating additional mutations other than BCR\u2237ABL1 may lead to TKI treatment failure or disease progression. We retrospectively evaluated 151 CML patients receiving TKI therapy and performed next-generation sequencing (NGS) analysis of 22 CML patients at diagnosis to explore the mutation spectrum other than BCR\u2237ABL1 affecting the achievement of molecular responses. The most frequently mutated gene was ASXL1 (40.9%). NOTCH3 and RELN mutations were only carried by subjects failing to achieve a major molecular response (MMR) at 12 months. The distribution frequency of ASXL1 mutations was higher in the group that did not achieve MR4.0 at 36 months (p = 0.023). The achievement of MR4.5 at 12 months was adversely impacted by the presence of &gt;2 gene mutations (p = 0.024). In the analysis of clinical characteristics, hemoglobin concentration (HB) and MMR were independent factors for deep molecular response (DMR), and initial 2GTKI therapy was better than 1GTKI in the achievement of molecular response. For the scoring system, we found the ELTS score was the best for predicting the efficacy of TKI therapy and the Socal score was the best for predicting mutations other than BCR\u2237ABL.<\/jats:p>","DOI":"10.3390\/cancers14235752","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T02:54:05Z","timestamp":1669258445000},"page":"5752","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR\u2237ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Shiwei","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-4948","authenticated-orcid":false,"given":"Xiaofei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"},{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4200-8636","authenticated-orcid":false,"given":"Jian","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, N1 Shangcheng Road, Yiwu 322000, China"},{"name":"Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou 310003, China"},{"name":"Department of Hematology, The First Affiliated Hospital of Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ajh.26455","article-title":"Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Patnaik","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref_7","first-page":"566","article-title":"Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: A multicenter retrospective clinical study","volume":"38","author":"Jiang","year":"2017","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: The EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/bcj.2013.54","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia","volume":"3","author":"Menezes","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2021-154273","article-title":"Mutational Profiles during the Progression of Chronic Myeloid Leukemia","volume":"138","author":"Xue","year":"2021","journal-title":"J. Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Schonfeld","year":"2022","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2021-150020","article-title":"Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1038\/onc.2008.230","article-title":"Notch3: From subtle structural differences to functional diversity","volume":"27","author":"Bellavia","year":"2008","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s12032-022-01651-w","article-title":"In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma","volume":"39","author":"Ghosal","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Schwarz, A., Roeder, I., and Seifert, M. (2022). Comparative Gene Expression Analysis Reveals Similarities and Differences of Chronic Myeloid Leukemia Phases. Cancers, 14.","DOI":"10.3390\/cancers14010256"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e15222","DOI":"10.1097\/MD.0000000000015222","article-title":"Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-022-01527-y","article-title":"A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1080\/03007995.2017.1356708","article-title":"Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib","volume":"33","author":"Ko","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/16078454.2020.1765563","article-title":"Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era","volume":"25","author":"Liu","year":"2020","journal-title":"Hematology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12185-021-03216-5","article-title":"Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year followup of the Japanese subgroup of the randomized ENESTnd trial","volume":"115","author":"Nakamae","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1002\/cam4.3516","article-title":"The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort","volume":"9","author":"Sato","year":"2020","journal-title":"Cancer Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","article-title":"Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5752\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:24:54Z","timestamp":1760145894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/23\/5752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":33,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["cancers14235752"],"URL":"https:\/\/doi.org\/10.3390\/cancers14235752","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]}}}